-+ 0.00%
-+ 0.00%
-+ 0.00%

D. Boral Capital Maintains Buy on Compass Therapeutics, Maintains $32 Price Target

Benzinga·04/28/2025 15:27:51
Listen to the news
D. Boral Capital analyst Jason Kolbert maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $32 price target.